Overview

Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi 400mcg Film Coated Tablets (400 mcg Selexipag)

Status:
COMPLETED

Trial end date:
2025-03-25

Target enrollment:

Participant gender:

Summary

Randomized, single oral dose, two-period, two-treatment, two-sequence open-label, crossover, bioequivalence study to compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) versus Uptravi 400mcg Film Coated Tablets (400 mcg Selexipag), in healthy subjects under fed conditions.

Phase:

PHASE1

Details

Lead Sponsor:

Humanis Saglk Anonim Sirketi

Treatments:

selexipag